Determining the Tolerance of Depigmented Skin to Targeted Phototherapy Using UVB in Patients With Vitiligo

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2008-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if vitiligo patients develop tolerance to ultraviolet light therapy, a type of treatment available for vitiligo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Narrowband UVB Treatment in Patients With Vitiligo

NCT00398723

Vitiligo

COMPLETED NA

Comparing the Efficacy of Visible Light-Ultraviolet A1 Light Versus Narrowband-Ultraviolet B on Generalized Vitiligo

NCT05238077

Generalized Vitiligo

TERMINATED NA

Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy

NCT03270241

Vitiligo Dermatology/Skin - Other

COMPLETED NA

Contribution of Skin Color in Stabilization of Active Cases of Vitiligo by Narrow Band UVB

NCT04030988

Vitiligo

UNKNOWN PHASE1

The Effect of UVB Phototherapy With Microneedling and Circled Needing in Vitiligo Patients

NCT03718962

Brief Description of Focus of Study Instead

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with vitiligo received 6-9 ultraviolet B treatments, 2 to 3 times weekly. Minimal erythema dose (MED) testing was done at baseline and after all treatments; the percent change in MED was analysed as a measure of photoadaptation. The percent decrease in cyclobutane pyrimidine dimers (CPDs) over 24 hours after a single exposure of 1 MED was analysed on vitiliginous and normal skin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitiligo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

6 to 9 ultraviolet B treatments

Treatments with ultraviolet B with gradually progressive doses

Intervention Type PROCEDURE

Skin biopsies

4 mm punch biopsies of the skin

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

phototherapy Skin biopsy, skin sample

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For inclusion, the subject must:

1. Be at least 18 years old
2. Be otherwise healthy
3. Have a diagnosis of vitiligo affecting \> 5% body surface area (BSA)
4. Have two depigmented lesions on opposite sides of the body that can be biopsied at the end of TARGETED UVB PHOTOTHERAPY treatment
5. Agree to abide by the Investigator's guidelines regarding photosensitizing drugs
6. Have a negative pregnancy test at baseline if female of childbearing potential
7. Be able to understand the requirements of the study, the risks involved, and is able to sign the informed consent form
8. Agree to follow and undergo all study-related procedures

Exclusion Criteria

Subjects will be excluded if any of the following apply:

1. Women who are lactating, pregnant, or planning to become pregnant
2. Patients with a recent history of serious systemic disease
3. Patients with a known history of photosensitivity
4. Concomitant use of systemic or topical treatments for vitiligo. Patients must discontinue PUVA or oral corticosteroid therapy for 4 weeks prior to the start of any treatment. If a patient is taking any vitamins or dietary supplements, the patient must discontinue them for the duration of the study. Topical therapy such as corticosteroids, topical immunomodulators (e.g., Protopic or Elidel), vitamin D derivatives (e.g., Dovonex), or UVB phototherapy must be discontinued for 2 weeks prior to the start of study treatment.
5. Patients diagnosed to be immunosuppressed for any reason (e.g., HIV infection, lupus, cancer, organ transplant, or chronic use of oral immunosuppressive agents).
6. Any reason the investigator feels the patient should not participate in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes